17 Potential Alzheimer’s Drugs to Be Focus of Alzheimer’s Talks Teleconference on April 11

17 Potential Alzheimer’s Drugs to Be Focus of Alzheimer’s Talks Teleconference on April 11
Two important Alzheimer’s research organizations, Researchers Against Alzheimer’s (RA2) and Us Against Alzheimer’s (UsA2), will host an Alzheimer’s Talks Teleconference on April 11 to discuss recently released findings of an analysis of late-stage drug candidates to treat the disease. Significant findings in the analysis, released in March, include:
  • There are 17 drugs in late-stage development (Phase 3 clinical trials), with the potential to be launched in the next five years
  • To prepare for the market release of one if not more of these drugs, the American healthcare system needs to make significant improvements in the following five areas:
    1. Enhancing the training and numbers of front-line physicians, including in primary care, to diagnose and treat Alzheimer’s
    2. Improving the accuracy of diagnosis
    3. Improving communication between patients and physicians
    4. Treating Alzheimer's as a fatal disease and improving patient access to clinical care (average wait time for a neurologist visit is now 35 days)
    5. Addressing payment and reimbursement (Currently, there is no assurance that the Centers for Medicare and Medicaid Services (CMS) or other national health payment authorities and insurance providers will pay for or reimburse for Alzheimer’s treatments.)
In a
Subscribe or to access all post and page content.